🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against superbug strains of the infection, according to scientists.

A Global Public Health Issue

Gonorrhoea infections are escalating globally, with estimates suggesting more than 82 million instances each year. Notably increased rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely development in the face of increasing worldwide cases, escalating drug resistance and the very limited treatment choices presently on offer.”

Health officials are deeply concerned about the surge in treatment-resistant strains. The WHO has listed it as a "priority pathogen". Recent surveillance found that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Secure Authorization

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US FDA in recent days for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts hope that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is employed against UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization GARDP collaborated with the drug firm its industry partner to see it through.

“This milestone marks a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which previously has been outpacing medical innovation.”

Research Study Results and Worldwide Availability

As per data detailed in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of cases of the STI. This establishes an comparable level with the typical regimen, which involves an injection and a pill. The study involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the rights to license and sell the drug in numerous regions with limited resources.

Clinicians directly involved have voiced optimism. Access to a easy-to-administer therapy of this kind is described as a "revolutionary step" for gonorrhoea control. This is deemed crucial to alleviate the strain of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea globally.